NCT00516646View on ClinicalTrials.gov

The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure

PHASE2CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

October 31, 2009

Conditions

Heart Failure

Interventions

DRUG

ALT-711

200 mg bid

DRUG

Placebo

bid

Trial Locations (1)

9700 RB

Dept. Cardiology - University Medical Center Groningen, Groningen

All Listed Sponsors

lead

Synvista Therapeutics, Inc

INDUSTRY

NCT00516646 - The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure | Biotech Hunter | Biotech Hunter